How to Cite
Abstract
The management of the SARS CoV2 pandemic, which emerged in 2020, imposed a level of demand on health personnel that had not been experienced in the last 100 years, not only due to the volume of cases, but also due to the difficulties in diagnosing and treatment. The interest in knowing the pathophysiology of post-COVID-19 symptoms and determining the influence of inflammation on them led to the performance of a descriptive observational clinical study with 125 outpatients, finding, in most of the patients, the persistence of the bronchus-alveolar and systemic inflammatory process, which determined the appearance of symptoms after infection by the biological particle, as well as showed the satisfactory evolution of those who were treated with Deflazacort at a dose of 6 mg per day in combination with inhaled fluticasone, as observed when evaluating the patients' conditions in terms of oxygen saturation, exertional dyspnea, hemodynamic parameters; such as blood pressure, heart rate and other symptoms such as polyarthralgias related to the normalization of inflammatory parameters such as ESR and CRP; allowing us to conclude that the use of steroids helps control the post-COVID-19 inflammatory process and therefore favors the resolution of these symptoms.
Keywords
References
Pulido. La gripe española, la pandemia de 1918. 19 de enero, 2018. Disponible a partir de: https://gacetamedica.com
Organización Mundial de la Salud (OMS). Información básica sobre la COVID 19. 28 de marzo, 2023. Disponible a partir de: https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-covid-19.
Organización Mundial de la Salud (OMS). Brote de enfermedad por coronavirus (COVID-19). Disponible a partir de: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019
Panamerican Health Organization/World Health Organization. COVID-19 Americas` Regional Dashboard. Geographic Distribution of cases and Death. Available from: https://www.arcgis.com/apps/dashboards/efb745c3d88647779beccb91c0e715f9
Instituto Nacional de Estadística e Informática. Biblioteca Virtual Población y Vivienda. Lima, Perú. Disponible a partir de: https://www.gob.pe/inei/
Ministerio de Salud de Perú. Información epidemiológica [Internet]. Disponible a partir de: https://covid19.minsa.gob.pe/sala_situacional.asp
Organización Mundial de la Salud. Enfermedad por coronavirus (COVID-19): afección posterior a la COVID-19. 28 de marzo, 2023. Disponible a partir de: https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition
Acosta, A. Secuelas del Covid–disminución de la presión 19, un desafío de la salud pública. Vive Rev Salud. 2023;5:196
Ruiz-Bravo A, Jiménez-Valera M. SARS-CoV-2 y pandemia de síndrome respiratorio agudo (COVID-19). Ars Pharmaceutica. 2020 [citado el 13 de diciembre, 2021]. Disponible a partir de: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-98942020000200001 [ Links ]
Gea J. Posibles limitaciones en la utilización de la presión parcial de oxígeno en procesos respiratorios por SARS-CoV2. Archivos de Bronconeumología. 2020;5:9-10.
Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes MM, Pilishvili T. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12-March 28, 2020. Morb Mortal Wkly Rep. 2020;69:382–386. DOI: 10.15585/mmwr.mm6913e2.
Blanco M. Controlar la tormenta de citoquinas, clave en los casos graves de Covid-19. 20 de abril, 2021. Disponible a partir de: https://www.uam.es/uam/noticias/tormenta-citoquinas-covid-19-hiperreaccion
Cimas JE. Seguimiento de los pacientes con secuelas no respiratorias de la COVID-19. FMC Form Medica Contin en Aten Primaria. National Library of Medicine. 2021;28(2):819. Disponible a partir de: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909903/
Salazar, Barochiner, Espeche. COVID-19, hipertensión y enfermedad cardiovascular. 09 de abril, 2020. Disponible a partir de: www.elsevier.es/hipertensión
Saltos Bazurto G, Hernández Castro M, Sánchez Núñez D... Bravo Cedeño I. Análisis de las complicaciones post-COVID-19 en pacientes con Enfermedades crónicas no trasmisibles. Revista Científica Higía de la Salud. 2020;3(2). DOI: https://doi.org/10.37117/higia.v1i3.467
Torres A. Indecencia de hipertensión arterial en adultos postcovid 19 en usuarios de una unidad de primer nivel de atención. 2023. Disponible a partir de: https://repositorioinstitucional.uaslp.mx/xmlui/handle/i/8197
Centro para el Control y la Prevención de Enfermedades CDC. National Health Statistics. Enfermedad del Coronavirus 2019. [Consultado el 09 de junio, 2020]. Disponible a partir de: https://www.cdc.gov/mis/mis-c.html
RECOVERY. Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19. Junio, 2020. Disponible a partir de: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19%20
Iturbide L, Palacios J. El papel de los corticoesteroides en pacientes hospitalizados por Covid-19 en el hospital general de México. Cir. cir. 16 de mayo, 2023:91(2).
Aure G, Carrera-Viñoles F, Requiz ZA. Esteroides y Covid; una revisión de la evidencia en crecimiento durante la pandemia. Revista Digital de Postgrado Facultad de Medicina, UCV. 2021;10(2). E312 Mayo-agosto. ISSN:2244-761X
Norris S, Schwartz N, Patel P. Case Series of Multisystem inflammatory Syndrome in Adults Associated with SARS-CoV-2 infection – United Kingdom and Unites States, March – August 2020. Centers for Disease Control and Prevention. Oct 09, 2020. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6940e1.htm
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020. DOI: 10.1001/jama.2020.5394.
Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. March 28, 2020;395(10229):1033-1034.
Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE: Goodman & Gilman´s – The pharmacological Basis of Therapeutics 10th Edition. New York: McGraw-Hill; 2001. p.1649-1677.
Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18:1.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Array